RIBOFLAVIN 5'-PHOSPHATE

Summary

Riboflavin 5’-Phosphate (CHEMBL1201794) is an approved small-molecule coenzyme; indicated across 1 condition including keratoconus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 456.3 Da · C17H21N4O9P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201794
Name	RIBOFLAVIN 5’-PHOSPHATE
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	643976
ChEBI	CHEBI:17621
Molecular formula	C17H21N4O9P
Molecular weight	456.3
InChIKey	FVTCRASFADXXNN-SCRDCRAPSA-N

SMILES: CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O

IUPAC name: [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate

ChEBI definition: A flavin mononucleotide that is riboflavin (vitamin B2) in which the primary hydroxy group has been converted to its dihydrogen phosphate ester.

Pharmacological roles (ChEBI): coenzyme, cofactor.

Other ChEBI roles (chemical / environmental): bacterial metabolite, human metabolite, mouse metabolite.

Also known as: E101a, Flavin mononucleotide, Riboflavin 5’-phosphate, Riboflavin phosphate, Vitamin b2 phosphate, RIBOFLAVIN 5’-PHOSPHATE, Riboflavin 5’-phosphate sodiumÊ, Riboflavin 5’-phosphate sodiumÂ, Riboflavin-5’-phosphate, riboflavin phosphate

Parent form; salt/anhydrous children: CHEMBL3989697

Patent coverage: 2,667 distinct patent families (7,348 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,341 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Glucocorticoid receptor, Estrogen receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Voltage-dependent L-type calcium channel subunit alpha-1C, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.05	AC50	900	nM	CHEMBL_ACT_25174483
ADRB2	5.54	AC50	2900	nM	CHEMBL_ACT_25233622
ESR1	5.43	AC50	3700	nM	CHEMBL_ACT_25167389
ADRA1A	5.29	AC50	5100	nM	CHEMBL_ACT_25218130

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
keratoconus	0	MONDO:0015486	MONDO:0015486

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03245853	PHASE4	COMPLETED	Epi-On Corneal Crosslinking for Keratoconus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).